Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Seiler

Obstetrics & Gynecology Haslett, MI Doctor of Osteopathy

NPI 1831159847 CMS profile 264907

1650 Haslett Rd, Haslett, MI 48840

Open in the dashboard

General payments

$35,240

202 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Seiler of Haslett, MI is reported in the CMS Open Payments database as having received $35,240 across 202 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $353 14
2024 General $636 28
2023 General $13,755 43
2022 General $16,156 55
2021 General $1,876 27
2020 General $389 11
2019 General $2,075 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Seiler
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Robert Seiler were reported at $353. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year Robert Seiler Obstetrics & Gynecology median Middle half National median
2019 $2,075 $172 $62–$391 $163
2020 $389 $94 $36–$222 $114
2021 $1,876 $136 $42–$369 $132
2022 $16,156 $160 $50–$433 $149
2023 $13,755 $169 $56–$423 $160
2024 $636 $152 $50–$371 $164
2025 $353 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Organon LLC $18,831 24 payments
  2. Myriad Women's Health, Inc. $6,126 7 payments
  3. Myriad Genetic Laboratories, Inc. $2,800 2 payments
  4. Merck Sharp & Dohme Corporation $2,592 12 payments
  5. Hologic, LLC $657 13 payments
  6. Vermillion, Inc. $421 5 payments
  7. AbbVie, Inc. $366 19 payments
  8. Sumitomo Pharma America, Inc. $278 14 payments
  9. Myovant Sciences Inc. $254 10 payments
  10. Ethicon US, LLC $250 2 payments
  11. Other $2,666 94 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for serving as faculty or as a speaker for a medical education program $18,677 16 payments
  2. Honoraria $8,750 6 payments
  3. Food and Beverage $5,258 177 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,406 2 payments
  5. Travel and Lodging $149 1 payment
Products named General payments · program years 2019–2025
  1. NEXPLANON Etonogestrel $18,809 23 payments
  2. myRisk Oncology $6,126 7 payments
  3. myRisk Germline Dna Sequencing Hereditary Cancer And Rearrangement Analysis $2,800 2 payments
  4. NEXPLANON Womens Health $2,445 6 payments
  5. MYFEMBREE $477 21 payments
  6. OVA1 $421 5 payments
  7. ORILISSA $235 9 payments
  8. ZYNRELEF $219 3 payments
  9. ORIAHNN $190 6 payments
  10. LO LOESTRIN FE $176 12 payments
  11. Other $4,677 162 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

59

Median for Obstetrics & Gynecology: 65

Drug cost

$15,630

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

52.5%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 11 $13,010
Estradiol Generic 28 $2,234
Progesterone Progesterone, Micronized Brand 20 $386

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$9,323

Medicare's payments for the services billed

Medicare patients

40

Average age 62

Services billed

101

40 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 53%
Arthritis 48%
Depression 35%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MYFEMBREE
  • Sumitomo Pharma America, Inc. $74
  • PFIZER INC. $5
$79 — —
GARDASIL 9
  • Merck Sharp & Dohme Corporation $32
$32 — —
GARDASIL
  • Merck Sharp & Dohme Corporation $32
$32 — —
ABRYSVO
  • PFIZER INC. $17
$17 — —
ZEPBOUND
  • Lilly USA, LLC $17
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

202 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics & Gynecology in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record